T/FIF Portfolio Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: LLCF who wrote (1031)	7/7/1999 4:15:00 PM
From: Gary Mohilner	Read Replies (1) of 1073

Have you followed what's happening with ImmunoGen. At the London Conference it was announced that in addition to previously announced drugs that are preceeding into Phase 1, the company is working with third party MAB's for Breast and Prostate Cancer. They also are anticipating drug filings that will generate $30 million from the Biochem Pharma Partnership. Over the next 6 months or so, I believe IMGN will have substantial news on several fronts with their first drug well into Phase 1 trials, the second drug about to go into trial, and 2 or more drugs developed by BCHE utilizing screens provided by them approaching trials. It should be an exciting 6 months. Gary

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next